// App-Quantinova.ai

431 : Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept

Researchers

Presenter

  • Pedro Machado

Principal Investigators

  • Ana Lúcia Martins Fernandes

  • Ana Pinto

  • Kalveer flora

  • dilpreet matharu

  • anthony isaacs

Medical Centers

  • Centro Hospitalar Universitário do Algarve, Faro, Portugal

  • Local Health Unit of Guarda, Barcelos, Portugal

  • Rheumatology, Northwick Park Hospital, Harrow, United Kingdom

  • Kings College London, London, United Kingdom

Locations

  • Portugal

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • TNF Receptor Superfamily Member 1B

Drug/Treatment

  • Adalimumab

  • Etanercept

  • CHS-0214

  • Etanercept biosimilar

Outcome

  • N/A

Study Design

  • Observational

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved